a public good project by the
Synthesis
Company
of California

© 2026

Gordon W. Rewcastle | doi.page

0 works0 citations0 h-index

Gordon W. Rewcastle

Cancer Society of New Zealand(NZ)

Publications by Year

Research Areas

Synthesis and biological activity, PI3K/AKT/mTOR signaling in cancer, Cancer therapeutics and mechanisms, Bioactive Compounds and Antitumor Agents, Synthesis and Characterization of Heterocyclic Compounds

Most-Cited Works

→ Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor(1996)321 cited
→ Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of minimal DNA-intercalating agents which may not act via topoisomerase II(1990)309 cited
→ Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions(2000)263 cited
→ Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.(1995)260 cited
→ Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling(2007)226 cited

→ Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids(1991)

194 cited

→ Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide(1987)188 cited

→ Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[d]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor(1999)178 cited

→ A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types(2011)170 cited

→ Tyrosine Kinase Inhibitors. 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor(1996)149 cited